In Brief: Expanded Heart Failure Indication for Empagliflozin (Jardiance)
Date: April 18, 2022
Issue #:
1648Summary:
The sodium-glucose cotransporter 2 (SGLT2) inhibitor
empagliflozin (Jardiance– Boehringer Ingelheim)
was approved by the FDA in 2021 to reduce the
risk of hospitalization for heart failure (HF) and
cardiovascular death in patients with heart failure
with reduced ejection fraction (HFrEF; LVEF ≤40%),
regardless of whether or not they have type 2
diabetes. The indication h as now been expanded to
include patients with HF with any ejection fraction.
Empagliflozin is the first SGLT2 inhibitor to be
approved in the US for this indication.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: canagliflozin dapagliflozin empagliflozin ertugliflozin Farxiga Forxiga Heart Failure Invokana Jardiance Steglatro type 2 diabetes Source Type: research
More News: Canagliflozin | Cardiology | Cardiovascular | Dapagliflozin | Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Empagliflozin | Endocrinology | Forxiga | Heart | Heart Failure | Invokana | Jardiance | SGLT2 Inhibitors | Sodium